EA030319B1 - Антитела, нейтрализующие rsv, mpv и pvm, и их применения - Google Patents
Антитела, нейтрализующие rsv, mpv и pvm, и их применения Download PDFInfo
- Publication number
- EA030319B1 EA030319B1 EA201491724A EA201491724A EA030319B1 EA 030319 B1 EA030319 B1 EA 030319B1 EA 201491724 A EA201491724 A EA 201491724A EA 201491724 A EA201491724 A EA 201491724A EA 030319 B1 EA030319 B1 EA 030319B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibody
- binding fragment
- antigen
- antibodies
- infection
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pulmonology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261613197P | 2012-03-20 | 2012-03-20 | |
| US201261655310P | 2012-06-04 | 2012-06-04 | |
| PCT/IB2013/000627 WO2013140247A1 (en) | 2012-03-20 | 2013-03-14 | Antibodies that neutralize rsv, mpv and pvm and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201491724A1 EA201491724A1 (ru) | 2015-01-30 |
| EA030319B1 true EA030319B1 (ru) | 2018-07-31 |
Family
ID=48471031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201491724A EA030319B1 (ru) | 2012-03-20 | 2013-03-14 | Антитела, нейтрализующие rsv, mpv и pvm, и их применения |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US9498531B2 (enExample) |
| EP (1) | EP2828293B1 (enExample) |
| JP (4) | JP6445423B2 (enExample) |
| KR (1) | KR102149069B1 (enExample) |
| CN (2) | CN107880121B (enExample) |
| AU (1) | AU2013237087B2 (enExample) |
| BR (1) | BR112014023063A2 (enExample) |
| CA (1) | CA2865856C (enExample) |
| DK (1) | DK2828293T3 (enExample) |
| EA (1) | EA030319B1 (enExample) |
| ES (1) | ES2657470T3 (enExample) |
| IL (1) | IL234710A (enExample) |
| IN (1) | IN2014DN07299A (enExample) |
| NZ (1) | NZ630920A (enExample) |
| PL (1) | PL2828293T3 (enExample) |
| WO (1) | WO2013140247A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2865856C (en) * | 2012-03-20 | 2023-03-14 | Humabs Biomed Sa | Antibodies that neutralize rsv, mpv and pvm and uses thereof |
| WO2014115893A1 (ja) | 2013-01-28 | 2014-07-31 | 株式会社イーベック | ヒト・メタニューモウイルスに特異的なヒト抗体もしくはその抗原結合性断片 |
| TWI659968B (zh) | 2013-03-14 | 2019-05-21 | 再生元醫藥公司 | 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法 |
| US9139653B1 (en) * | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| WO2020160171A1 (en) * | 2019-01-29 | 2020-08-06 | Sanford Burnham Prebys Medical Discovery Institute | Topically formulated antibody compositions for reducing pathogen transmission and methods of using same |
| US12559544B2 (en) | 2019-05-21 | 2026-02-24 | University Of Georgia Research Foundation, Inc. | Antibodies that bind human metapneumovirus fusion protein and their use |
| US20240101648A1 (en) * | 2021-02-09 | 2024-03-28 | Humabs Biomed Sa | Antibodies against respiratory syncytial virus, human metapneumovirus and pneumonia virus of mice and methods of using the same |
| CA3209869A1 (en) * | 2021-02-26 | 2022-09-01 | Fred Hutchinson Cancer Center | Protective antibodies against respiratory viral infections |
| CN115466326B (zh) * | 2021-06-11 | 2024-06-04 | 中国科学院微生物研究所 | 一种呼吸道合胞病毒的人源单克隆抗体及其应用 |
| CA3235979A1 (en) * | 2021-12-06 | 2023-06-15 | Xiamen University | Antibody for recognizing rsv pre-f protein and use thereof |
| EP4743488A1 (en) * | 2023-07-13 | 2026-05-20 | Vir Biotechnology Inc | Antibodies widely neutralizing against paramyxoviruses RSV and MPV |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004092207A2 (en) * | 2003-04-16 | 2004-10-28 | Algonomics N.V. | Respiratory syncytial virus (rsv) peptides |
| US20060228367A1 (en) * | 2005-04-08 | 2006-10-12 | Medimmune, Inc. | Antibodies against mammalian metapneumovirus |
| WO2010149743A2 (en) * | 2009-06-24 | 2010-12-29 | Id Biomedical Corporation Of Quebec | Vaccine |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3766162A (en) | 1971-08-24 | 1973-10-16 | Hoffmann La Roche | Barbituric acid antigens and antibodies specific therefor |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| SG149684A1 (en) | 2001-01-19 | 2009-02-27 | Vironovative Bv | A virus causing respiratory tract illness in susceptible animals |
| AU2003210060B2 (en) | 2002-03-22 | 2010-02-25 | Aprogen, Inc. | Humanized antibody and process for preparing same |
| WO2004010935A2 (en) * | 2002-07-25 | 2004-02-05 | Medimmune, Inc. | Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies |
| AU2004215125B2 (en) | 2003-02-26 | 2011-01-06 | Institute For Research In Biomedicine | Monoclonal antibody production by EBV transformation of B cells |
| EP1473037A1 (en) | 2003-05-02 | 2004-11-03 | Vironovative B.V. | Treatment of hPMV infections with Ribavirin |
| EP1997830A1 (en) * | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| DK2350128T3 (da) | 2008-10-22 | 2014-12-01 | Inst Research In Biomedicine | Fremgangsmåder til fremstilling af antistoffer fra plasmaceller |
| DK2464664T3 (da) * | 2009-08-13 | 2016-01-18 | Crucell Holland Bv | Antistoffer mod humant respiratorisk syncytialvirus (rsv) og fremgangsmåder til anvendelse deraf |
| EP2591000B1 (en) * | 2010-07-09 | 2017-05-17 | Janssen Vaccines & Prevention B.V. | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use |
| CA2865856C (en) * | 2012-03-20 | 2023-03-14 | Humabs Biomed Sa | Antibodies that neutralize rsv, mpv and pvm and uses thereof |
-
2013
- 2013-03-14 CA CA2865856A patent/CA2865856C/en active Active
- 2013-03-14 NZ NZ630920A patent/NZ630920A/en not_active IP Right Cessation
- 2013-03-14 CN CN201711120146.XA patent/CN107880121B/zh not_active Expired - Fee Related
- 2013-03-14 ES ES13724357.2T patent/ES2657470T3/es active Active
- 2013-03-14 US US13/827,845 patent/US9498531B2/en active Active
- 2013-03-14 DK DK13724357.2T patent/DK2828293T3/en active
- 2013-03-14 JP JP2015501002A patent/JP6445423B2/ja active Active
- 2013-03-14 AU AU2013237087A patent/AU2013237087B2/en not_active Ceased
- 2013-03-14 WO PCT/IB2013/000627 patent/WO2013140247A1/en not_active Ceased
- 2013-03-14 EP EP13724357.2A patent/EP2828293B1/en active Active
- 2013-03-14 KR KR1020147029324A patent/KR102149069B1/ko not_active Expired - Fee Related
- 2013-03-14 BR BR112014023063A patent/BR112014023063A2/pt not_active IP Right Cessation
- 2013-03-14 PL PL13724357T patent/PL2828293T3/pl unknown
- 2013-03-14 CN CN201380026218.8A patent/CN104350069B/zh active Active
- 2013-03-14 EA EA201491724A patent/EA030319B1/ru unknown
-
2014
- 2014-08-29 IN IN7299DEN2014 patent/IN2014DN07299A/en unknown
- 2014-09-17 IL IL234710A patent/IL234710A/en active IP Right Grant
-
2016
- 2016-08-10 US US15/233,026 patent/US10072071B2/en active Active
-
2018
- 2018-08-09 US US16/059,408 patent/US20190153073A1/en not_active Abandoned
- 2018-11-29 JP JP2018224174A patent/JP6722264B2/ja not_active Expired - Fee Related
-
2020
- 2020-05-27 US US16/885,009 patent/US11421020B2/en active Active
- 2020-06-19 JP JP2020106004A patent/JP7069251B2/ja not_active Expired - Fee Related
-
2022
- 2022-05-02 JP JP2022076023A patent/JP2022132244A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004092207A2 (en) * | 2003-04-16 | 2004-10-28 | Algonomics N.V. | Respiratory syncytial virus (rsv) peptides |
| US20060228367A1 (en) * | 2005-04-08 | 2006-10-12 | Medimmune, Inc. | Antibodies against mammalian metapneumovirus |
| WO2010149743A2 (en) * | 2009-06-24 | 2010-12-29 | Id Biomedical Corporation Of Quebec | Vaccine |
Non-Patent Citations (2)
| Title |
|---|
| LING R, PRINGLE C R: "Polypeptides of pneumonia virus of mice. I. Immunological cross-reactions and post-translational modifications.", JOURNAL OF GENERAL VIROLOGY., SOCIETY FOR GENERAL MICROBIOLOGY, SPENCERS WOOD., GB, vol. 70, no. part 6, 1 June 1989 (1989-06-01), GB, pages 1427 - 1440, XP002699618, ISSN: 0022-1317, DOI: 10.1099/0022-1317-70-6-1427 * |
| M. MAGRO, V. MAS, K. CHAPPELL, M. VAZQUEZ, O. CANO, D. LUQUE, M. C. TERRON, J. A. MELERO, C. PALOMO: "Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 109, no. 8, 21 February 2012 (2012-02-21), pages 3089 - 3094, XP055067847, ISSN: 00278424, DOI: 10.1073/pnas.1115941109 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2553325C2 (ru) | Нейтрализующие антитела против вируса гриппа а и их использование | |
| JP5710123B2 (ja) | ヒトサイトメガロウイルス中和抗体およびその使用 | |
| JP6062477B2 (ja) | ヒトサイトメガロウイルス中和抗体およびその使用 | |
| JP5475774B2 (ja) | ヒトサイトメガロウイルス中和抗体およびその使用 | |
| JP6722264B2 (ja) | Ｒｓｖ、ｍｐｖおよびｐｖｍを中和する抗体およびその利用 | |
| CN108610416B (zh) | 登革热病毒中和抗体及其用途 | |
| JP7747353B2 (ja) | 抗コロナウイルス完全ヒト広域スペクトル中和抗体７６ｅ１及びその適用 | |
| US20250361291A1 (en) | Monoclonal antibodies against jc virus | |
| JPWO2016139941A1 (ja) | 抗体、フラグメント、分子及び抗ｈｃｖ治療剤 | |
| EA039682B1 (ru) | Антитела, нейтрализующие rsv, mpv и pvm, и их применения | |
| JP2014087349A (ja) | ヒトサイトメガロウイルス中和抗体およびその使用 | |
| HK1206367B (en) | Antibodies that neutralize rsv, mpv and pvm and uses thereof |